| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Cancer Research Program, Garvan Institute of Medical Research, St Vincent’s Hospital, Darlinghurst, New South Wales 2010, Australia
2 St. Vincent’s Clinical School, Faculty of Medicine, University of New South Wales, Randwick, New South Wales 2052, Australia
(Requests for offprints should be addressed to R L Sutherland; Email: r.sutherland{at}garvan.org.au)
This paper was presented at the 1st Tenovus/AstraZeneca Workshop, Cardiff (2005). AstraZeneca has supported the publication of these proceedings.
Antioestrogen therapy is a highly effective treatment for patients with oestrogen-receptor (ER)-positive breast cancer, emphasising the central role of oestrogen action in the development and progression of this disease. However, effective antioestrogen treatment is often compromised by acquired endocrine resistance, prompting the need for a greater understanding of the down-stream mediators of oestrogen action that may contribute to this effect. Recent studies have demonstrated a critical link between oestrogen’s mitogenic effects and cell cycle progression, particularly at the G1 to S transition where key effectors of oestrogen action are c-Myc and cyclin D1, which converge on the activation of cyclin E-cdk2. These components are rapidly upregulated in response to oestrogen, and can mimic its actions on cell cycle progression, including re-initiating cell proliferation in antioestrogen-arrested cells. Here we review the roles of c-Myc, cyclin D1 and cyclin E in oestrogen action and endocrine resistance, and identify their potential as markers of disease progression and endocrine responsiveness, and as novel therapeutic targets in endocrine-resistant breast cancer.
This article has been cited by other articles:
|
|
 |
|
  N. Ogba, L. J. Chaplin, Y. Q. Doughman, K. Fujinaga, and M. M. Montano HEXIM1 Regulates 17{beta}-Estradiol/Estrogen Receptor-{alpha}-Mediated Expression of Cyclin D1 in Mammary Cells via Modulation of P-TEFb Cancer Res., September 1, 2008; 68(17): 7015 - 7024. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rudas, M. Lehnert, A. Huynh, R. Jakesz, C. Singer, S. Lax, W. Schippinger, O. Dietze, R. Greil, W. Stiglbauer, et al. Cyclin D1 Expression in Breast Cancer Patients Receiving Adjuvant Tamoxifen-Based Therapy Clin. Cancer Res., March 15, 2008; 14(6): 1767 - 1774. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. De los Santos, O. Martinez-Iglesias, and A. Aranda Anti-estrogenic actions of histone deacetylase inhibitors in MCF-7 breast cancer cells Endocr. Relat. Cancer, December 1, 2007; 14(4): 1021 - 1028. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. X. Zou, A. S. Revenko, L. B. Li, A. T. Gemo, and H.-W. Chen ANCCA, an estrogen-regulated AAA+ ATPase coactivator for ER{alpha}, is required for coregulator occupancy and chromatin modification PNAS, November 13, 2007; 104(46): 18067 - 18072. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. G. Roberts, E. Gurisik, T. J. Biden, R. L. Sutherland, and A. J. Butt Synergistic cytotoxicity between tamoxifen and the plant toxin persin in human breast cancer cells is dependent on Bim expression and mediated by modulation of ceramide metabolism Mol. Cancer Ther., October 1, 2007; 6(10): 2777 - 2785. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Deschenes, V. Bourdeau, J. H. White, and S. Mader Regulation of GREB1 Transcription by Estrogen Receptor {alpha} through a Multipartite Enhancer Spread Over 20 kb of Upstream Flanking Sequences J. Biol. Chem., June 15, 2007; 282(24): 17335 - 17339. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Naciff, G. J. Overmann, S. M. Torontali, G. J. Carr, Z. S. Khambatta, J. P. Tiesman, B. D. Richardson, and G. P. Daston Uterine Temporal Response to Acute Exposure to 17{alpha}-Ethinyl Estradiol in the Immature Rat Toxicol. Sci., June 1, 2007; 97(2): 467 - 490. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Kilker and M. D. Planas-Silva Cyclin D1 Is Necessary for Tamoxifen-Induced Cell Cycle Progression in Human Breast Cancer Cells Cancer Res., December 1, 2006; 66(23): 11478 - 11484. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Vivacqua, D. Bonofiglio, L. Albanito, A. Madeo, V. Rago, A. Carpino, A. M. Musti, D. Picard, S. Ando, and M. Maggiolini 17beta-Estradiol, Genistein, and 4-Hydroxytamoxifen Induce the Proliferation of Thyroid Cancer Cells through the G Protein-Coupled Receptor GPR30 Mol. Pharmacol., October 1, 2006; 70(4): 1414 - 1423. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Butt, C. G. Roberts, A. A. Seawright, P. B. Oelrichs, J. K. MacLeod, T. Y.E. Liaw, M. Kavallaris, T. J. Somers-Edgar, G. M. Lehrbach, C. K. Watts, et al. A novel plant toxin, persin, with in vivo activity in the mammary gland, induces Bim-dependent apoptosis in human breast cancer cells. Mol. Cancer Ther., September 1, 2006; 5(9): 2300 - 2309. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J M W Gee, A Howell, W J Gullick, C C Benz, R L Sutherland, R J Santen, L-A Martin, F Ciardiello, W R Miller, M Dowsett, et al. Consensus Statement Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S1 - S7. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
